MENG-KUN TSAIChu S.H.REY-HENG HUChiang Y.J.SHIH-CHIEH CHUEHLai M.K.PO-HUANG LEE2021-08-022021-08-0220010041-1345https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035671416&doi=10.1016%2fS0041-1345%2801%2902358-2&partnerID=40&md5=06fe606286ecf242ea53e261270bd12ehttps://scholars.lib.ntu.edu.tw/handle/123456789/575486[SDGs]SDG2[SDGs]SDG3antivirus agent; baktar; cyclosporin A; ganciclovir; interleukin 2 receptor antibody; methylprednisolone; nystatin; prednisolone; tacrolimus; unclassified drug; adolescent; adult; article; clinical article; controlled study; cytomegalic inclusion body disease; drug blood level; drug efficacy; drug safety; female; graft failure; graft survival; hemodialysis; human; immunosuppressive treatment; infection prevention; kidney allograft; kidney graft rejection; kidney transplantation; male; postoperative complication; priority journal; survival rate; Taiwan; treatment outcome; virus infection; Antibodies, Monoclonal; Cyclosporine; Drug Therapy, Combination; Female; Graft Rejection; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Male; Recombinant Fusion Proteins; Taiwanjournal article10.1016/S0041-1345(01)02358-2117503692-s2.0-0035671416